🔗 Share this article

The recently developed medications for gonorrhoea in decades are being hailed as a "major milestone" in the battle against superbug strains of the infection, according to health experts.

A Worldwide Health Concern

The sexually transmitted infection are on the rise worldwide, with estimates suggesting in excess of 82 million new cases each year. Particularly high rates are reported in Africa and countries within the WHO's designated area, which spans from Mongolia and China to New Zealand. Across England, cases have reached a record high, while figures across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of fresh medications for gonorrhoea is an important and timely step in the face of growing infection rates, escalating drug resistance and the very limited treatment choices at this time.”

Medical experts are particularly alarmed about the rise in antibiotic-resistant strains. The WHO has classified it as a "high-priority threat". Ongoing monitoring revealed that the effectiveness of key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Receive Clearance

One new antibiotic, also known as a brand name, was authorized by the American regulatory agency in December for use against gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Scientists believe that targeted use of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, originating from the pharmaceutical company GSK, was also approved in the same week. This drug, which is also used to treat UTIs, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment emerged from a new, not-for-profit approach for drug creation. The charitable organization GARDP worked alongside the pharmaceutical company Innoviva to develop it.

“This authorization represents a huge turning point in the management of highly resistant gonorrhoea, which until now has been outpacing antibiotic development.”

Clinical Trial Outcomes and Worldwide Availability

As per findings detailed in a prominent scientific publication, zoliflodacin eradicated the vast majority of genital gonorrhoea infections. This establishes an comparable level with the typical regimen, which uses a dual-drug approach. The trial involved over 900 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, GARDP has the authority to register and commercialise the drug in a wide range of developing nations.

Clinicians directly involved have shared optimism. Access to a single-dose, oral treatment such as this is seen as a "revolutionary step" for public health efforts. This is viewed as crucial to alleviate the strain of the disease for individuals and to stop the proliferation of highly drug-resistant gonorrhoea around the world.